Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MOB.STthis companyMoberg Pharma AB (publ)	SEK 10.26	-17.71×	0.72×	35.54×	-9.58×	-46.1%	56.7%	-206.8%	-201.2%	-4.1%	-4.2%	-12.6%	0×	8.66×	-157.29×	14.71×	0.0%	4	15.41	3	B
ACARIX.STAcarix AB (publ)	SEK 0.16	-6.28×	7.91×	41.02×	-6.37×	-225.0%	37.5%	-652.2%	-653.3%	-126.0%	-125.8%	-16.3%	0×	0.41×	0×	4.08×	0.0%	3	12.43	1	D+
ACE.STAscelia Pharma AB (publ)	SEK 0.54	-4.81×	3.67×	0×	-4.32×	-17.7%	0.0%	0.0%	0.0%	-76.7%	-73.4%	-19.8%	0.01×	0.67×	-13.46×	4.35×	0.0%	1	-8.91	2	C+
ALZCUR.STAlzeCure Pharma AB	SEK 6.42	-4.26×	6.11×	0×	-3.24×	-92.8%	0.0%	0.0%	0.0%	-144.8%	-139.1%	-17.2%	0.16×	0.94×	-180.85×	2.33×	0.0%	5	15.15	3	B+
ENZY.STEnzymatica AB (publ)	SEK 2.35	-9.05×	3.71×	8.56×	-9.17×	-287.0%	61.5%	-96.9%	-96.3%	-41.8%	-41.7%	-8.9%	0.01×	0.69×	-42.41×	3.65×	0.0%	4	10.82	1	C-
ERMA.STEnorama Pharma AB (publ)	SEK 0.76	-1.77×	-5.66×	48.45×	-2.1×	-104.0%	-2255.6%	-2268.0%	-2743.3%	320.4%	264.9%	-44.7%	0×	0.05×	-4.91×	0.25×	0.0%	2	-29.47	2	C
Peer median	—	-4.81×	3.71×	8.56×	-4.32×	-104.0%	0.0%	-96.9%	-96.3%	-76.7%	-73.4%	-17.2%	0.01×	0.67×	-13.46×	3.65×	0.0%	3	10.82	2	—